Publication:
Concurrent chemoradiotherapy with low dose weekly gemcitabine in stage III non-small cell lung cancer

Simple item page
dc.contributor.authorYUMUK, PERRAN FULDEN
dc.contributor.authorsAbacioglu, U; Yumuk, PF; Caglar, H; Sengoz, M; Turhal, NS
dc.date.accessioned2022-03-14T09:12:44Z
dc.date.available2022-03-14T09:12:44Z
dc.date.issued2005-12
dc.description.abstractBackground: Combined chemoradiotherapy (CRT) is the treatment of choice for stage III NSCLC. Gemcitabine (G) is a novel deoxycitidine analogue that has been proven to be a potent radiosensitizer. Twenty-two consecutive patients were treated with concurrent CRT to demonstrate the tolerability and efficacy of low dose G given weekly as radiosensitizer in stage III NSCLC. Methods: Patients with KPS >= 70, adequate bone marrow reserve, with no prior radiotherapy (RT) and surgery were included. Eighteen patients had received prior induction chemotherapy (CT). G (75 mg/m(2)/week) was infused over 1 hour for 6 weeks. Thoracic RT was given two hours later over 6 weeks at 1.8 Gy/day fractions (total dose of 61.2 Gy). Pulmonary toxicity was evaluated with computed tomography scans in 6 weeks. Results: Median age was 60 years (range, 48-75), median follow-up was 15 months (range, 2-40). Sixty-eight percent of patients were male and median KPS score was 90. Conformal 3D-RT planning was used in 64% of patients. G was given for a median of 5 weeks ( range 1-9). Twelve patients (54.6%) received all planned CT. G was stopped because of intolerance in 6 and death in 2 patients. Seven patients (31.8%) had radiation pneumonitis. Twenty patients were evaluated for overall response, 1 patient (4.5%) had clinical CR, 81.8% had PR while 9.5% had SD. Median overall survival (OS) was 14 +/- 5 months (95% CI 3-25). One- and 2-year OS rates were 55% and 38%. Sixteen patients died of disease-related events (6 with progression of primary tumor, 8 due to metastatic disease), 2 patients died of other causes. One- and 2-year progression- free survival and local control rates were 56%, 27% and 79%, 51%, respectively. Conclusion: G might be used as radiosensitizer for patients with stage III NSCLC who could not receive full doses CT with concurrent RT.
dc.identifier.doi10.1186/1471-2407-5-71
dc.identifier.eissn1471-2407
dc.identifier.pubmed16000167
dc.identifier.urihttps://hdl.handle.net/11424/242769
dc.identifier.wosWOS:000231068200001
dc.language.isoeng
dc.publisherBMC
dc.relation.ispartofBMC CANCER
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectTWICE-WEEKLY GEMCITABINE
dc.subjectLEUKEMIA GROUP-B
dc.subjectPHASE-I TRIAL
dc.subjectRADIOTHERAPY
dc.subjectCHEMOTHERAPY
dc.subjectRADIATION
dc.subjectPACLITAXEL
dc.subjectCISPLATIN
dc.subjectRADIOSENSITIZATION
dc.subjectSURVIVAL
dc.titleConcurrent chemoradiotherapy with low dose weekly gemcitabine in stage III non-small cell lung cancer
dc.typearticle
dspace.entity.typePublication
local.avesis.id1e822ac8-4101-4530-b443-24945f6c638e
local.import.packageSS16
local.indexed.atWOS
local.indexed.atSCOPUS
local.indexed.atPUBMED
local.journal.articlenumber71
local.journal.numberofpages7
oaire.citation.titleBMC CANCER
oaire.citation.volume5
relation.isAuthorOfPublication4e7b3d69-6d73-4c60-89e4-d6fddfddd2aa
relation.isAuthorOfPublication.latestForDiscovery4e7b3d69-6d73-4c60-89e4-d6fddfddd2aa

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Abacioglu et al. - 2005 - Concurrent chemoradiotherapy with low dose weekly .pdf
Size:
223.68 KB
Format:
Adobe Portable Document Format
Download

Collections

Research Outputs